Postoperative Outcomes of the Largest HeartMate-II Experience in Turkey
Articles > Article · 2015
Authors: Serkan ERTUGAY, Çağatay ENGİN, Sanem NALBANTGİL, S. Kocabas, O. BALCIOGLU, Y. ENGIN, Tahir YAĞDI, Mustafa ÖZBARAN
TRANSPLANTATION PROCEEDINGS, Journal Indexed in SCI Expanded, International, 2015, vol 47, pp 1499-1502
DOI: 10.1016/j.transproceed.2015.04.046
Summary
Introduction. HeartMate II (HMII; Thoratec Corporation, Pleasanton, Calif, United States) is a continuous-flow pump approved by the Food and Drug Administration (FDA) for bridge-to-transplantation (BIT) since 2008 and for destination therapy (DT) since 2010. Herein, we present the postoperative outcomes of HMII implantation due to end-stage heart failure in our center.